E

Emerging key trends in hematologic malignancies

Emerging trends in hematology

February 25, 2026
E

How to achieve superior BCMA response rates without the liability of delayed MNTs

An interesting conundrum in myeloma space...

February 23, 2026
E

Is AstraZeneca’s surovatamig underappreciated?

Are the late entrants in lymphomas me-toos or next gen agents capable of moving the needle?

January 16, 2026
E

ASH25 – the great menin shakeout

Jockeying for position in the menin AML niche

December 10, 2025
E

The end of forever pills – CLL17 data and the BTK degrader controversy

New developments in CLL are a mixed bag so far

December 8, 2025
E

ASH Highlights from Day 1 – AML, MDS, and Myeloma

A look at key data from the SAVE trial, TecLille, and other gems...

December 7, 2025
E

ASH25 Preview – 10 abstracts to watch out for

Important early stage trials to watch out for in Orlando

December 3, 2025
E

ASH25 Preview 1: BTK degraders mature while others face durability challenges

Some protein degraders are finally looking promising while the next generation DACs may turn a few heads

November 4, 2025